Abstract | BACKGROUND: METHODS: In this Institutional Review Board-approved study, we retrospectively analyzed the records of 8 adult patients treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens. We determined radiographic response (Macdonald criteria), median time to progression ( TTP), and median overall survival (OS; Kaplan-Meier method). RESULTS: There were 4 men and 4 women with a median age of 40 years (range, 20-65). Prior treatment included surgery (n = 8), RT (8), temozolomide (5), and carboplatin (4). Bevacizumab (5-15 mg/kg every 2-3 weeks) was administered alone (2) or concurrently with cytotoxic chemotherapy including irinotecan (3), carboplatin (2), or temozolomide (1). Six patients achieved a partial response (75%) and 1 remained stable for over 8 months. Median TTP was 6.4 months (95% confidence interval 1.4-7.4) and median OS was 9.4 months (95% confidence interval 7.0-not reached), with a median follow-up of 5.2 months among 5 surviving patients (63%). CONCLUSIONS: The radiographic response rate to bevacizumab-containing regimens is high. A prospective study is warranted.
|
Authors | R M Green, T F Cloughesy, R Stupp, L M DeAngelis, E A Woyshner, D E Ney, A B Lassman |
Journal | Neurology
(Neurology)
Vol. 73
Issue 20
Pg. 1677-80
(Nov 17 2009)
ISSN: 1526-632X [Electronic] United States |
PMID | 19917990
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Bevacizumab
|
Topics |
- Adult
- Aged
- Angiogenesis Inhibitors
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Brain Neoplasms
(drug therapy, mortality, therapy)
- Disease Progression
- Drug Therapy, Combination
- Ependymoma
(drug therapy, mortality, therapy)
- Female
- Follow-Up Studies
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy, mortality, therapy)
- Retrospective Studies
- Time Factors
- Treatment Outcome
- Young Adult
|